The short version of research chemical fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-08-02 and is reviewed periodically as new material appears.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
The island is known for using geothermal energy to provide electricity for its inhabitants. In San Carlos, Negros Occidental where energy company San Carlos Solar Energy (SaCaSol) is located, solar energy is being used to power the city and surrounding municipalities. Inland towns and cities of Negros uses hydroelectric power acquired from springs, rivers and waterfalls. Due to the island region's sugarcane-based agriculture, Negros may become the nation's major biofuel producer, with sugarcane being used for ethanol production.
=== Society === Nigeria has been generating most of its revenue from oil industry for the past 30 years. However, since petroleum industry has appeared, many pollution problems have risen in Nigeria. The major problem was caused by oil spills, occurring during usual operations. From 1976 to 1988, 2000 oil spillages happened in Nigeria and more than two million barrels of bonny light oil were released to the community during this period. Additionally, break of oil pipelines, erosion of flow and trunk lines, and hose failure are the causes of oil spills. Consequently, both the aquatic milieu and environment had detrimental impacts by them. These ecosystems are key element in agricultural productivity and main source for Nigerians, inhabiting in the oil-producing areas, to live. Therefore, some activists in Nigeria have spoiled pipelines, and key infrastructures which are related to crude oil and export flows are usually targeted. As a result, the issue related to oil effusion in Nigeria has been exacerbated. In Nigeria, microbial seeding is being considered instead of mechanical ways by the main oil companies for the purpose of cleaning up oil spills.
=== Recurring === Isabella Rossellini as Franny Forst, Byron's estranged wife Nicola Peltz Beckham as Franny after the transformation John Carroll Lynch as FBI Supervisor Meyer Williams Patrick Luwis as Meyer after the transformation Rob Yang as Dr. Ray Lee, a scientist and the original developer of the "Beauty" drug who now works for Byron Ari Graynor as Dr. Diana Sterling, a roboticist and the creator of the "Deacons"
Sources: en.wikipedia.org
From ancient times until the advent of the modern era, the most widely worn traditional dress in India was draped. For women, it took the form of a sari, a single piece of cloth many yards long. The sari was traditionally wrapped around the lower body and the shoulder. In its modern form, it is combined with an underskirt, or Indian petticoat, and tucked in along the waistband for more secure fastening. It is also commonly worn with an Indian blouse, or choli, which serves as the primary upper-body garment; the sari's end passes over the shoulder, covering the midriff and obscuring the upper body's contours. For men, a similar but shorter length of cloth, the dhoti, has served as a lower-body garment. The use of stitched clothes became widespread after Muslim rule was established by the Delhi Sultanate (c. 1300 CE) and continued by the Mughal Empire (c. 1525 CE). Among the garments introduced during this time and still commonly worn are: the shalwars and pyjamas, both styles of trousers, and the tunics kurta and kameez. Shalwars are atypically wide at the waist but narrow to a cuffed bottom. A drawstring holds them up, causing them to pleat at the waist. When the pants are cut quite narrow, on the bias, they are called churidars. The kameez is a long shirt or tunic. Its side seams left open below the waistline. The kurta is traditionally collarless and made of cotton or silk; it is worn plain or with embroidered decoration, such as chikankari; and typically falls to either just above or just below the wearer's knees.
=== Skin === Human skin has a limited capacity for regeneration, and wound healing therefore typically results in scar formation. In contrast, fetal skin is capable of healing without scarring, a phenomenon that has prompted research into the mechanisms underlying scarless healing and their potential application to regenerative therapies in adults.
To commemorate the occasion, the airline named the McDonnell Douglas MD-11 operating the inaugural flight Elvis 1 and gave each passenger gifts, among them a small bottle of Jack Daniel's whiskey. In preparation for the flight, the airport had constructed a new customs facility. In 1997, Northwest acquired Express Airlines I, a regional carrier that operated under the Northwest Airlink brand, and shifted its headquarters to Memphis. The airport served 11.8 million travelers in 2000. The Memphis–Shelby County Airport Authority expanded the facilities. The passenger terminal was enlarged five times between 1986 and 1999. Northwest and the airport authority worked together on the fifth project. They added 15 gates to Concourse A for Express I's new 50-seat Bombardier CRJs. Other upgrades included a post-security corridor linking Concourses B and C, a new lounge, and faster ticket counters. A third parallel runway opened in 1997. Three years later, the middle runway was rebuilt and lengthened to 11,120 feet (3,390 m). Dubbed the World Runway, it enabled KLM to take off from Memphis with a full cabin in hot conditions and FedEx to carry more cargo.
====== Interferons ====== Type I and type II interferons have anticancer activity (see the "Function" section in the "Interferon" article). Interferons can promote expression of major histocompatibility complex molecules, MHC I and MHC II, and stimulate immunoproteasome activity. All interferons drastically increase the presentation of MHC I dependent antigens. Interferon gamma (IFN-gamma) also strongly promotes the MHC II-dependent presentation of antigens. Higher MHC I expression leads to higher presentation of viral and abnormal peptides from cancer cells to cytotoxic T cells, while the immunoproteasome more efficiently processes these peptides for loading onto the MHC I molecule. Therefore, the recognition and killing of infected or malignant cells increases. Higher MHC II expression enhances presentation of viral and cancer peptides to helper T cells; which are releasing cytokines (such as more interferons, interleukins and other cytokines) that stimulate and co-ordinate the activity of other immune cells. By down regulation of angiogenic stimuli produced by tumor cells interferon can also suppress angiogenesis In addition, they suppress the proliferation of endothelial cells. Such suppression causes a decrease in tumor vascularization and subsequent growth inhibition. Interferons can directly activate immune cells including macrophages and natural killer cells. INF-1 and interferon gamma (IFN-γ) production are triggered by SeV molecular components in many cells (See "Virus-induced antiviral immunity" section above).
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.